SK Chemicals 2025 Corporate Governance Report: Strong Governance Structure with Minor Compliance Gaps
SK Chemicals disclosed its 2025 corporate governance report, emphasizing board-centered management and transparency, but failed to meet some core governance indicators such as shareholder meeting notice period (actual 12-19 days vs. recommended 4 weeks) and lack of formalized CEO succession policy, which may pose investment risks.
The board consists of 7 members including 4 outside directors, operating 5 committees including audit and internal transaction committees. However, cumulative voting is not yet adopted (expected in September 2026), potentially limiting minority shareholder rights.
In 2025, the company issued 220 billion KRW in exchangeable bonds (0% coupon, maturity 2030) to fully repay debt, with 3.82 million shares (4.88%) of SK Bioscience as the underlying asset. This reduces debt but poses potential dilution risk upon conversion.
Consolidated revenue reached 2.37 trillion KRW (+36.2% YoY), operating loss narrowed to 207 million KRW (from -45.2 billion), and net profit turned positive at 27.3 billion KRW, showing improving profitability but still operating loss.
The company maintained a 30% payout ratio on separate net income, paying cash dividends of 1,150 won for common and 1,200 won for preferred shares (yield 2.1%/4.5%). However, the absence of a new mid-term dividend policy after the previous one expired reduces dividend predictability.
[AI Comprehensive Analysis]SK Chemicals' governance structure is generally solid, but minor non-compliances such as shortened shareholder meeting notice and lack of succession policy require improvement for value enhancement. The exchangeable bond issuance improved financial structure but carries potential dilution risk. Early establishment of a shareholder return policy is expected to positively impact the stock price.